Synosia Starts Phase II Efficacy Trial For Rufinamide



    Epilepsy Drug to be Tested as Treatment for Anxiety

    BASEL, Switzerland, March 31 /CNW/ - Synosia Therapeutics today announced
the start of a multi-site, Phase II clinical trial to evaluate the efficacy of
rufinamide (SYN-111), a sodium channel blocker, as a potential treatment for
general anxiety disorder.
    The trial is an eight-week, double-blind, placebo-controlled, exploratory
study being conducted in 20 sites in the United States. It will assess the
efficacy and tolerability of rufinamide in up to 230 patients with general
anxiety disorder, as measured by multiple psychometric assessment tools.
Patients randomized to rufinamide will receive 250mg twice a day for one week
followed by 500mg twice a day for seven weeks. The trial design was guided by
the encouraging results of a proof-of-concept study announced in January 2008.
    Rufinamide was discovered and developed by Novartis. Rights to SYN-111
were obtained by Synosia from Novartis in 2007 in an exclusive worldwide
licensing agreement, outside of Japan, to develop and commercialize rufinamide
for the treatment of anxiety and other mood disorders. Rufinamide is also
marketed by Eisai in Europe as a drug to treat a form of epilepsy under the
tradename Inovelon(R).
    "Given the extensive safety experience available from previous studies,
we believe this structurally novel compound has the potential to relieve
anxiety without the adverse side effects of current treatments," said Stephen
Bandak, Synosia's chief medical officer. "There is a real need for new
treatment options without the limited compliance associated with selective
serotonin reuptake inhibitors (SSRIs) or the risk of dependence of
benzodiazepine-based treatments."
    It is estimated that over 62 million people in the United States and the
five major European pharmaceutical markets suffer from a form of anxiety. Of
those, over nine million suffer from general anxiety disorder.(1),(2)

    About Rufinamide

    The drug was originally discovered and developed by Novartis, which in
2004 granted certain licensing rights to Eisai, excluding anxiety and mood
disorders. In January 2007, Eisai received marketing authorisation in the
European Union for Inovelon(R) (rufinamide) as adjunctive anti-epileptic
therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that
develops in early childhood. The extensive clinical development program for
rufinamide in epilepsy has generated over 2500 patient years of exposure to
the drug.

    About Synosia Therapeutics

    Synosia Therapeutics develops and intends to commercialize innovative and
clinically differentiated products for unmet medical needs in psychiatry and
neurology. The privately-owned company has six clinical-stage compounds in its
pipeline, acquired through key partnerships with Novartis, Roche and Syngenta.
Synosia's pipeline includes two marketed drugs that will be tested in new
indications, extending their reach into neurological and psychiatric diseases
with high unmet medical need, including anxiety and Parkinson's Disease.
Synosia's headquarters is in Basel, Switzerland. For more information visit
http://www.synosia.com

    Disclaimer

    This communication expressly or implicitly contains certain
forward-looking statements concerning Synosia Therapeutics and its business.
Such statements involve certain known and unknown risks, uncertainties and
other factors which could cause the actual results, financial condition,
performance or achievements of Synosia Therapeutics to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements.
    Synosia Therapeutics is providing this communication as of this date and
does not undertake to update any forward-looking statements contained herein
as a result of new information, future events or otherwise.

    References

    (1) Demyttenaere et al. Prevalence, Severity, and unmet needs for
treatment of mental disorders in the WHO World Mental Surveys. JAMA (2004)
vol. 291 (21) pp. 2581-90.

    (2) Kessler et al. Lifetime prevalence and age-of-onset distributions of
DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen
Psychiatry (2005) vol. 62 (6) pp. 593-602.





For further information:

For further information: Synosia Therapeutics, Julie Walters at Tudor
Reilly, Tel: +44(0)1494-753-990, Mobile +44(0)775-3626967,
julie.walters@tudor-reilly.com; In the US, Michele Parisi at Tudor Reilly,
Tel: (925) 864-5028, michele.parisi@tudor-reilly.com; In Switzerland: Martin
Meier-Pfister or Jan Gregor at The IR Firm, Tel: +41-43-244-81-54, Mobile:
+41-79-652-36-20, synosia@irfirm.biz

Organization Profile

SYNOSIA THERAPEUTICS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890